Skip to main content
. Author manuscript; available in PMC: 2013 Apr 25.
Published in final edited form as: Nature. 2012 Sep 19;490(7421):502–507. doi: 10.1038/nature11531

Figure 2. IL-12-induced CD8α+ cDCs in Batf3−/− mice can cross-present and mediate tumor rejection.

Figure 2

a, From mice in Fig. 1c, DCs were purified by sorting as CD3DX5MHCII+CD11c+Sirp-αCD24+DEC205+ DCs (CD8DC) and CD3DX5MHCII+CD11c+Sirp-α+CD24DEC205 DCs (CD4DC) and assayed for cross-presentation7. OT-I proliferation in response to cDCs mixed with the indicated number of MHC class I-deficient ovalbumin (Ova)-loaded splenocytes is shown. b, Wild type (WT) or Batf3−/− (BATF3 KO) mice treated with vehicle (PBS) or with IL-12 (IL12) were inoculated with 1×106 H31m1 fibrosarcomas. Tumor size in individual mice is shown. c, Mice in (b) were analyzed by FACS 11 days after H31m1 inoculation for CD8 T cell infiltration into tumors7.

HHS Vulnerability Disclosure